Brief: Transgene Q1 Operating Revenue Down At 2.4 Million Euros

Transgene SA

27/04/2021 17:21

April 27 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE REPORTS BUSINESS UPDATE AND END Q1 2021
FINANCIAL
POSITION
    * TG4001 - REGULATORY CLEARANCE RECEIVED FOR RANDOMIZED
PHASE II
TRIAL - FIRST PATIENT EXPECTED TO BE ENROLLED IN 2Q 2021
    * EUR 19.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH
31,
2021 - FINANCIAL VISIBILITY UNTIL SECOND HALF OF 2022
    * DURING Q1 OF 2021, REVENUE FROM COLLABORATIVE AND
LICENSING
AGREEMENTS WAS MAINLY COMPOSED OF REVENUE FROM COLLABORATION
WITH ASTRAZENECA
    * Q1 OPERATING REVENUE EUR 2.4 MILLION VERSUS EUR 3.0
MILLION YEAR
AGO
    * FIRST PATIENTS DOSED IN PHASE I TRIAL EVALUATING BT-001,
AN
ONCOLYTIC VIRUS BASED ON INVIR.IO™ PLATFORM - FIRST DATA ARE
EXPECTED IN 1H 2022
    * FIRST PATIENTS DOSED WITH TG4050, INDIVIDUALIZED
THERAPEUTIC
VACCINE AGAINST CANCER BASED ON TRANSGENE'S MYVAC® TECHNOLOGY -
FIRST DATA FROM TWO ONGOING PHASE I CLINICAL TRIALS ARE EXPECTED
IN 4Q 2021

Source text for Eikon:  ID:nBwbqbVvQa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))